- Home
- ARVN vs SAR Comparison
ARVN vs SAR Comparison
Compare ARVN & SAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARVN
- SAR
- Stock Information
- Founded
- ARVN 2015
- SAR 2007
- Country
- ARVN United States
- SAR United States
- Employees
- ARVN N/A
- SAR N/A
- Industry
- ARVN Biotechnology: Pharmaceutical Preparations
- SAR Investment Managers
- Sector
- ARVN Health Care
- SAR Finance
- Exchange
- ARVN Nasdaq
- SAR Nasdaq
- Market Cap
- ARVN 456.2M
- SAR 383.6M
- IPO Year
- ARVN 2018
- SAR 2007
- Fundamental
- Price
- ARVN $6.79
- SAR $25.24
- Analyst Decision
- ARVN Buy
- SAR Hold
- Analyst Count
- ARVN 22
- SAR 4
- Target Price
- ARVN $20.21
- SAR $24.75
- AVG Volume (30 Days)
- ARVN 2.1M
- SAR 133.0K
- Earning Date
- ARVN 08-06-2025
- SAR 10-07-2025
- Dividend Yield
- ARVN N/A
- SAR 11.87%
- EPS Growth
- ARVN N/A
- SAR 105.87
- EPS
- ARVN N/A
- SAR 2.47
- Revenue
- ARVN $372,800,000.00
- SAR $142,495,705.00
- Revenue This Year
- ARVN $7.57
- SAR N/A
- Revenue Next Year
- ARVN N/A
- SAR $1.97
- P/E Ratio
- ARVN N/A
- SAR $10.23
- Revenue Growth
- ARVN 299.57
- SAR N/A
- 52 Week Low
- ARVN $5.90
- SAR $21.10
- 52 Week High
- ARVN $29.61
- SAR $26.49
- Technical
- Relative Strength Index (RSI)
- ARVN 41.59
- SAR 55.82
- Support Level
- ARVN $6.06
- SAR $24.32
- Resistance Level
- ARVN $7.83
- SAR $24.95
- Average True Range (ATR)
- ARVN 0.40
- SAR 0.42
- MACD
- ARVN -0.11
- SAR 0.03
- Stochastic Oscillator
- ARVN 34.93
- SAR 75.34
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
About SAR Saratoga Investment Corp New
Saratoga Investment Corp is a specialty finance company that provides customized financing solutions to U.S. middle-market businesses. The Company invests in senior and unitranche leveraged loans and mezzanine debt, and, to a lesser extent, equity to provide financing for change of ownership transactions, strategic acquisitions, recapitalizations and growth initiatives in partnership with business owners, management teams and financial sponsors. Its objective is to create attractive risk-adjusted returns by generating current income and long-term capital appreciation from its debt and equity investments.